Botulinum toxin in the treatment of orofacial tardive dyskinesia: A single blind study

Christina W. Slotema, Peter N. van Harten, Richard Bruggeman, Hans W. Hoek*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

25 Citations (Scopus)


Objective: Orofacial tardive dyskinesia (OTD) is difficult to treat and Botulinium Toxin A (BTA) may be an option.

Methods: In a single blind (raters were blind) study (N= 12, duration 33 weeks) OTD was treated with Botulinum Toxin A in three consecutive sessions with increasing dosages. The severity was measured with the Abnormal Involuntary Movement Scale (AIMS).

Results: Overall there was a non-significant reduction in the severity of OTD (p=0.15). However, in the patients with no change in their anti psychotic medication (N= 8) the reduction was significant (p=0.035). After the study, 50% of the patients preferred to continue the Botulinum Toxin A treatment.

Conclusion: BTA was well tolerated and showed a non-significant improvement for OTD. A larger double blind study is warranted. (c) 2007 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)507-509
Number of pages3
JournalProgress in Neuro-Psychopharmacology & Biological Psychiatry
Issue number2
Publication statusPublished - 15-Feb-2008
Event13th Biennial Winter Workshop on Schizophrenia Research - Davos, Switzerland
Duration: 4-Feb-200610-Feb-2006


  • antipsychotic agents
  • Botulinum toxin
  • orofacial tardive dyskinesia

Cite this